Liver cirrhosis, portal hypertension
Conditions
Interventions
The subjects with written informed consent are enrolled in this study from November, 2010 to April 2014. The subjects are consisted with control subjects. Those subjects are examined small intestine w
Sponsors
Ehime University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The people with or without liver cirrhosis who have a schedule to receive small-intestinal endoscopy. All enrolled participants provided written informed consent for the study under the protocols approved by the Institutional Review Boards of Ehime University Hospital (approved number: 1011004). The study protocol conformed to the ethical guidelines of the Declaration of Helsinki.
Exclusion criteria
Exclusion criteria: We exclude a patient who has a risk for bleeding by taking the intestinal biopsy specimen (for example, bleeding tendency, taking the anticoagulant drug).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analysis of the molecules associated with the absorption of fatty acids in the patients with liver cirrhosis with or without portal hypertension. | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunohistochemical analysis of the intestinal specimen in the patients with liver cirrhosis with or without portal hypertension. Moreover, analysis of the protein and mRNA levels of intestinal molecules associated with the transport of long-chain fatty acids in the patients with liver cirrhosis with or without portal hypertension. | — |
Countries
Japan
Contacts
Public ContactYasunori Yamamoto
Ehime University Graduate School of Medicine Department of Gastroenterology and Metabology
Outcome results
None listed